BBOT
HealthcareBridgeBio Oncology Therapeutics Inc. · Biotechnology · $680M
What is BridgeBio Oncology Therapeutics Inc.?
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology. It targets RAS and PI3Kα pathways — among the most common oncogene drivers in human cancers — with a pipeline of next-generation small molecule therapies.
BBOT develops small molecule drugs designed to block cancer-driving mutations in the KRAS and PI3K pathways. It recently went public through a business combination with Helix Acquisition Corp. II, raising substantial capital to fund clinical development. The company operates as a spin-out of BridgeBio Pharma, inheriting deep scientific expertise in precision oncology while pursuing its own independent pipeline.
The company was formed in 2025 and is headquartered in South San Francisco, California.
- BBO-8520 — KRAS-targeted small molecule program
- BBO-10203 — PI3Kα pathway inhibitor program
- BBO-11818 — additional RAS/PI3K oncology program
- Precision oncology platform focused on high-prevalence tumor mutations
Is BBOT a Good Stock to Buy?
UQS Score rates BBOT as Poor overall, reflecting the early-stage nature of its business and the significant uncertainties typical of clinical-stage biotechnology.
Among the five pillars, Risk comes in at Neutral — suggesting the company's balance sheet and near-term financial structure are not yet at the most extreme end of concern, likely supported by the capital raised at IPO.
Quality, Moat, Growth, and Valuation all register as Weak or Elevated, consistent with a pre-revenue company that has no approved products, no durable competitive advantages established, and a valuation that already prices in optimistic outcomes.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BBOT pay dividends?
No — BridgeBio Oncology Therapeutics Inc. does not currently pay a dividend.
BBOT does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward advancing pipeline programs through clinical trials. Income-focused investors should not expect distributions from BBOT in the near term.
When does BBOT report earnings?
BridgeBio Oncology Therapeutics reports on a quarterly cadence, as is typical for US-listed companies.
As a newly public, pre-revenue company, quarterly reports primarily reflect research and development spending and cash runway rather than commercial results. Investors should focus on clinical milestones and pipeline updates rather than traditional revenue metrics.
For the most recent quarterly results and pipeline updates, visit BridgeBio Oncology Therapeutics' investor relations page directly.
BBOT Price History
-8.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in BridgeBio Oncology Therapeutics Inc.?
Based on BridgeBio Oncology Therapeutics Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
BBOT Long-term Outlook
With Growth and Quality both rated Weak, BBOT's near-term trajectory depends almost entirely on clinical trial outcomes rather than organic business momentum. The Elevated Valuation label suggests the market has already priced in a degree of pipeline success that has yet to be demonstrated. The Neutral Risk rating provides some reassurance that the company is not in immediate financial distress, but the path to value creation remains long and binary in nature.
Growth drivers
- Positive clinical data readouts from BBO-8520, BBO-10203, or BBO-11818 programs
- Growing clinical and commercial interest in KRAS and PI3K inhibitors across oncology
- Capital raised at IPO providing runway to reach meaningful trial milestones
Key risks
- Clinical trial failure or delays across any pipeline program
- Elevated valuation leaving limited margin of safety if data disappoints
- Competitive pressure from larger, better-resourced oncology drug developers
BBOT vs Peers
BBOT operates in a crowded clinical-stage oncology space alongside several small-cap peers also pursuing targeted cancer therapies.
Jade Biosciences focuses on immuno-oncology approaches, offering a different mechanistic angle compared to BBOT's small molecule RAS/PI3K strategy.
SELLAS pursues cancer immunotherapy with peptide-based vaccine candidates, distinguishing it from BBOT's small molecule precision oncology focus.
Gyre Therapeutics targets fibrotic diseases and related oncology indications, giving it a partially overlapping but distinct therapeutic focus relative to BBOT.
Frequently Asked Questions
What does BridgeBio Oncology Therapeutics do?
BridgeBio Oncology Therapeutics develops small molecule drugs targeting RAS and PI3Kα mutations — two of the most common cancer-driving genetic alterations. The company's pipeline includes three programs aimed at KRAS and PI3K pathways. It is a clinical-stage company with no approved products yet.
Does BBOT pay dividends?
No, BBOT does not pay a dividend. As a clinical-stage biopharmaceutical company, it reinvests all available capital into research and clinical development. Dividend payments are not expected until the company reaches commercial-stage profitability, which remains a distant prospect.
When does BBOT report earnings?
BBOT reports financial results on a quarterly cadence. Because it is pre-revenue, reports focus on cash position and R&D expenditure rather than sales. Check BridgeBio Oncology Therapeutics' investor relations page for the most current reporting schedule.
Is BBOT a good stock to buy?
UQS Score rates BBOT as Poor overall, driven by Weak scores across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. This profile reflects the high uncertainty of clinical-stage biotech investing. Investors should weigh pipeline risk carefully. The full pillar breakdown is available to Pro members.
Is BBOT overvalued?
The UQS Valuation pillar for BBOT is rated Elevated, suggesting the current market price may already reflect optimistic assumptions about pipeline success. For a pre-revenue company, valuation is inherently speculative and tied to clinical outcomes rather than current financial performance.
How does BBOT compare to its competitors?
BBOT competes with other small-cap clinical-stage oncology companies including Jade Biosciences, SELLAS Life Sciences, and Gyre Therapeutics. BBOT's differentiation lies in its specific focus on KRAS and PI3Kα small molecule inhibitors, a mechanistic approach distinct from immunotherapy or vaccine-based peers.
What is BBOT's market cap bracket?
BBOT is classified as a small-cap stock. This places it in a segment of the market characterized by higher volatility, lower liquidity, and greater sensitivity to binary clinical events compared to large- or mega-cap healthcare companies.
Who founded BridgeBio Oncology Therapeutics?
BridgeBio Oncology Therapeutics was formed as a subsidiary of BridgeBio Pharma before going public in 2025 via a business combination with Helix Acquisition Corp. II. The company is led by CEO Dr. Eli Wallace and CSO Dr. Pedro Beltran. Full founding details are publicly available through the company's filings.
Is BBOT a long-term quality investment?
As a long-term quality indicator, BBOT's UQS profile is Poor, with Weak scores on Quality, Moat, and Growth. Long-term quality typically requires durable competitive advantages and consistent financial performance — neither of which a clinical-stage company can yet demonstrate. Pipeline success could change this picture materially over time.
What is the main competitive advantage of BridgeBio Oncology Therapeutics?
BBOT's potential edge lies in its scientific focus on KRAS and PI3Kα — high-value oncology targets with large patient populations. Its origins within BridgeBio Pharma provide access to established drug discovery expertise. However, the UQS Moat pillar is currently rated Weak, reflecting that no durable advantage has yet been established.
Unlock Full BBOT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS Score pillar breakdown for BBOT
- ✓Access underlying financial metrics and cash runway indicators
- ✓Compare BBOT side-by-side with clinical-stage oncology peers
- ✓Screen for higher-quality healthcare stocks using UQS filters
- ✓Get the full analyst-style quality view in one place
Pro Analysis
BBOT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | 14.4 | 0.0 | 14.0 | 0.0 | 72.5 | 0.0 | +3.2 |
| Apr 2, 2026 | 11.2 | 0.0 | 14.0 | 0.0 | 51.3 | 0.0 | — |
BBOT — Pillar Breakdown
Quality
— 0.0/100 (25%)BridgeBio Oncology Therapeutics Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)BridgeBio Oncology Therapeutics Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 72.5/100 (15%)BridgeBio Oncology Therapeutics Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)BridgeBio Oncology Therapeutics Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 14/100 (25%)BridgeBio Oncology Therapeutics Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BBOT.
Score Composition
Financial Data
More Stock Analysis
How is the BBOT UQS Score Calculated?
The UQS (Unified Quality Score) for BridgeBio Oncology Therapeutics Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses BridgeBio Oncology Therapeutics Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether BridgeBio Oncology Therapeutics Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.